Preterm labor is one of the problems of obstetrics, and is one of the leading cause of neonatal morbidity and mortality. The incidence of preterm birth is around 7 to 9 %. The preterm baby is prone to respiratory, renal, neurologic and gastrointestinal problems. The correct diagnosis should be followed by the early administration of the most effective tocolytic agent with least side effects for both mother and fetus. Nifedipine, a calcium channel blocker, has gained a world-wide popularity recently since it has the least side-effects on both mother and fetus. In the present study, we aimed to evaluate the success rate of tocolytic agent 'nifedipine' on the spontaneous preterm labor of singeton pregnant women with intact amnionic membrane.
Preterm birth is the main reason of perinatal morbidity and mortality. The main management method of this important problem is to prolong the pregnancy period and to use corticosteroids to prevent fetal pulmonary distress. The most widely studied tocolytic agents, ritodrin, salbutamol and terbutaline are all betamimetics, and they are shown to prolong birth labor till 7 days and do not have any effct on the fetal mortality. However, their maternal side-effects are inevitable and can be mortal. They cause tachycardia, hypotension and some biochemical disturbances. Furthermore, maternal death is possible due to pulmonary edema. These adrenergic agonists are the first line tocolytics, but calcium canal blockers are becoming more popular since they have less side effects and comparable efficacy. Calcium canal blockers are nonspecific smooth muscle relaxants used in adult hypertension treatment. Their tocolytic effect depends on their inhibition of calcium ions into the myometrial cells. In vitro studies have shown that they have strong relaxant effects on human myometrium. In the present study, our aim is to investigate the effects of nifedipine in our clinic in a period between 2002 and 2005, when it was first used in our clinic as the sıngle tocolytic agent. Its success in preventing preterm labor and its complications in our earlier practice will be noted and this retrospective study will guide us in its current usage, dosages and side-effects.
Study Type
OBSERVATIONAL
Enrollment
444
For both groups, when preterm labor is diagnosed, 10 mg capsule will be given sublinguially and if it is not effective in 1 hour, the same dose will be repeated again, and the same regimen will be repeated every day till preterm labor ends or proceed to a preterm birth.
Delay Delivery for 1 day
After start of tocolytic nifedipine, the delay recorded till delivery is only 24 hours
Time frame: 1 day
Delay Delivery for 2 days
After start of tocolytic nifedipine, the delay recorded till delivery is 48 hours
Time frame: 2 days
Delay Delivery for 3 days
After start of tocolytic nifedipine, the delay recorded till delivery is 72 hours
Time frame: 3 days
Delay Delivery for 7 days
After start of tocolytic nifedipine, the delay recorded till delivery is 168 hours
Time frame: 7 days
Birth before 34 weeks
After start of tocolytic nifedipine, the preterm birth occurs before 34 weeks
Time frame: till 34 weeks of gestation
Birth before 37 weeks
After start of tocolytic nifedipine, the preterm birth occurs before 37 weeks
Time frame: till 37 weeks of gestation
Birth after 37weeks
After start of tocolytic nifedipine, the preterm birth occurs after 37 weeks (Normal birth)
Time frame: after 37 weeks of gestation-normal birth
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.